Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Virax Biolabs Group's annualizedNet Income for the quarter that ended in Mar. 2026 was $-5.37 Mil. Virax Biolabs Group's average total tangible assets for the quarter that ended in Mar. 2026 was $7.02 Mil. Therefore, Virax Biolabs Group's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -76.50%.
The historical rank and industry rank for Virax Biolabs Group's Return-on-Tangible-Asset or its related term are showing as below:
VRAX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -3840.45 Med: -112.71 Max: -68.11
Current: -73.64
During the past 7 years, Virax Biolabs Group's highest Return-on-Tangible-Asset was -68.11%. The lowest was -3840.45%. And the median was -112.71%.
VRAX's Return-on-Tangible-Asset is ranked worse than 71.55% of 1413
companies
in the Biotechnology industry
Industry Median: -35.75
vs VRAX: -73.64
Virax Biolabs Group (NAS:VRAX) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Virax Biolabs Group Return-on-Tangible-Asset Related Terms
Virax Biolabs Group Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virax Biolabs Group Return-on-Tangible-Asset Chart
VRAX vs ISCO, PKTX, GRI: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Virax Biolabs Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -76.50% mean?
Virax Biolabs Group (VRAX) has a Return-on-Tangible-Asset of -76.50% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Virax Biolabs Group and its competitors. According to the industry distribution chart, Virax Biolabs Group ranks #1011 out of 1413 companies in the Biotechnology industry, placing it in the top 71.5%.
Is Virax Biolabs Group's Return-on-Tangible-Asset too high?
Virax Biolabs Group's current Return-on-Tangible-Asset is -76.50%. Based on the distribution chart, Virax Biolabs Group ranks #1011 out of 1413 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Virax Biolabs Group has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Return-on-Tangible-Asset compare to ISCO and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #1011 out of 1413 companies for Return-on-Tangible-Asset. This places Virax Biolabs Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Virax Biolabs Group and its competitors. Virax Biolabs Group's current Return-on-Tangible-Asset is -76.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.62, compared to a current price of $3.04 — trading 16% below its estimated fair value. The current Return-on-Tangible-Asset is -76.50%. Virax Biolabs Group's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Return-on-Tangible-Asset is -76.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be undervalued.
The current stock price of $3.04 is trading 16% below its estimated GF Value™ of $3.62.
GuruFocus considers Virax Biolabs Group to be Modestly Undervalued.
Key valuation signals for VRAX:
Return-on-Tangible-Asset: -76.50%
GF Value™: $3.62 vs. price of $3.04 (16% below fair value)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
45GF Score
Get the complete analysis for VRAX
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
